Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB003 in advanced malignancies with KIT or PDGFRα alterations
NCT04936178Phase 1Completed
- Sponsor
- Ningbo NewBay Technology Development Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of NB003 in gastrointestinal stromal tumor (GIST), melanoma and solid tumor (advanced stage), sponsored by Ningbo NewBay Technology Development Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 24 months, Adverse Events at 26 months and 2 more. Started Aug 2021; status: completed.
02
Drugs
NB003
03
Conditions
gastrointestinal stromal tumor (GIST)melanomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04936178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936178.